Chronic activation of human cardiac fibroblasts in vitro attenuates the reversibility of the myofibroblast phenotype

[1]  M. Gladka,et al.  Single-cell transcriptomics following ischemic injury identifies a role for B2M in cardiac repair , 2021, Communications biology.

[2]  R. J. van der Geest,et al.  Left ventricular fibrosis and hypertrophy are associated with mortality in heart failure with preserved ejection fraction , 2021, Scientific reports.

[3]  Catherine L. Worth,et al.  Cells of the adult human heart , 2020, Nature.

[4]  S. Cook,et al.  Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle? , 2020, EMBO molecular medicine.

[5]  S. Turley,et al.  A Potent Pan-TGFβ Neutralizing Monoclonal Antibody Elicits Cardiovascular Toxicity in Mice and Cynomolgus Monkeys. , 2020, Toxicological sciences : an official journal of the Society of Toxicology.

[6]  M. Peters-Golden,et al.  Molecular determinants of mesenchymal cell activation in fibroproliferative diseases , 2019, Cellular and Molecular Life Sciences.

[7]  I. Dixon,et al.  An Improved Method of Maintaining Primary Murine Cardiac Fibroblasts in Two-Dimensional Cell Culture , 2019, Scientific Reports.

[8]  H. Roderick,et al.  Myofibroblast Phenotype and Reversibility of Fibrosis in Patients With End-Stage Heart Failure. , 2019, Journal of the American College of Cardiology.

[9]  P. Zorlutuna,et al.  Effect of Substrate Stiffness on Mechanical Coupling and Force Propagation at the Infarct Boundary. , 2018, Biophysical journal.

[10]  Megan L. McCain,et al.  Featured Article: TGF-β1 dominates extracellular matrix rigidity for inducing differentiation of human cardiac fibroblasts to myofibroblasts , 2018, Experimental biology and medicine.

[11]  Marco Valgimigli,et al.  2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). , 2018, European heart journal.

[12]  Cécile M. Bidan,et al.  Tensile forces drive a reversible fibroblast-to-myofibroblast transition during tissue growth in engineered clefts , 2018, Science Advances.

[13]  A. McCulloch,et al.  Mechanical regulation of cardiac fibroblast profibrotic phenotypes , 2017, Molecular biology of the cell.

[14]  J. Molkentin,et al.  Redefining the identity of cardiac fibroblasts , 2017, Nature Reviews Cardiology.

[15]  Tong Liu,et al.  Current Understanding of the Pathophysiology of Myocardial Fibrosis and Its Quantitative Assessment in Heart Failure , 2017, Front. Physiol..

[16]  F. Charpentier,et al.  Transforming growth factor &bgr; receptor inhibition prevents ventricular fibrosis in a mouse model of progressive cardiac conduction disease , 2017, Cardiovascular research.

[17]  M. Czubryt,et al.  Regulation of fibronectin gene expression in cardiac fibroblasts by scleraxis , 2016, Cell and Tissue Research.

[18]  Xiao-ming Meng,et al.  TGF-β: the master regulator of fibrosis , 2016, Nature Reviews Nephrology.

[19]  J. Holmes,et al.  A computational model of cardiac fibroblast signaling predicts context-dependent drivers of myofibroblast differentiation. , 2016, Journal of molecular and cellular cardiology.

[20]  Alexander V. Panfilov,et al.  Effects of Heterogeneous Diffuse Fibrosis on Arrhythmia Dynamics and Mechanism , 2016, Scientific Reports.

[21]  P. Kohl,et al.  Fibroblast-myocyte coupling in the heart: Potential relevance for therapeutic interventions. , 2016, Journal of molecular and cellular cardiology.

[22]  M. Yacoub,et al.  Functional crosstalk between cardiac fibroblasts and adult cardiomyocytes by soluble mediators. , 2015, Cardiovascular research.

[23]  J. Baselga,et al.  Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study , 2014, Cardiovascular Toxicology.

[24]  S. Akhter,et al.  β-Arrestins regulate human cardiac fibroblast transformation and collagen synthesis in adverse ventricular remodeling. , 2014, Journal of molecular and cellular cardiology.

[25]  K. Credille,et al.  Nonclinical Safety Evaluation of a Transforming Growth Factor β Receptor I Kinase Inhibitor in Fischer 344 Rats and Beagle Dogs , 2014 .

[26]  Peter Kohl,et al.  Fibroblast–myocyte electrotonic coupling: Does it occur in native cardiac tissue?☆ , 2014, Journal of molecular and cellular cardiology.

[27]  O. Frazier,et al.  Fibrosis and heart failure , 2014, Heart Failure Reviews.

[28]  B. Hinz.  Matrix mechanics and regulation of the fibroblast phenotype. , 2013, Periodontology 2000.

[29]  Tevfik F Ismail,et al.  Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. , 2013, JAMA.

[30]  P Zhang,et al.  Cross talk between cardiac myocytes and fibroblasts: from multiscale investigative approaches to mechanisms and functional consequences. , 2012, American journal of physiology. Heart and circulatory physiology.

[31]  April M. Kloxin,et al.  Redirecting Valvular Myofibroblasts into Dormant Fibroblasts through Light-mediated Reduction in Substrate Modulus , 2012, PloS one.

[32]  T. Wynn,et al.  Mechanisms of fibrosis: therapeutic translation for fibrotic disease , 2012, Nature Medicine.

[33]  M. Anderton,et al.  Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors , 2011, Toxicologic pathology.

[34]  V. Thannickal,et al.  Reversible differentiation of myofibroblasts by MyoD. , 2011, Experimental cell research.

[35]  Y. Pinto,et al.  Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. , 2011, Cardiovascular research.

[36]  E. Kardami,et al.  Cardiac fibroblast to myofibroblast differentiation in vivo and in vitro: Expression of focal adhesion components in neonatal and adult rat ventricular myofibroblasts , 2010, Developmental dynamics : an official publication of the American Association of Anatomists.

[37]  C. Rosendorff,et al.  Association between transforming growth factor-beta(1) and left ventricular mass and diameter in hypertensive patients. , 2010, Journal of the American Society of Hypertension : JASH.

[38]  T. Wynn,et al.  Cellular and molecular mechanisms of fibrosis , 2008, The Journal of pathology.

[39]  J. Bomser,et al.  Inhibition of cardiac fibroblast proliferation and myofibroblast differentiation by resveratrol. , 2005, American journal of physiology. Heart and circulatory physiology.

[40]  A. Seth,et al.  Mechanical force regulation of myofibroblast differentiation in cardiac fibroblasts. , 2003, American journal of physiology. Heart and circulatory physiology.

[41]  B. Hinz,et al.  Myofibroblasts and mechano-regulation of connective tissue remodelling , 2002, Nature Reviews Molecular Cell Biology.

[42]  K. Huse,et al.  Aldosterone and d-Glucose Stimulate the Proliferation of Human Cardiac Myofibroblasts In Vitro , 2002, Hypertension.

[43]  V. Petrov,et al.  Stimulation of Collagen Production by Transforming Growth Factor-&bgr;1 During Differentiation of Cardiac Fibroblasts to Myofibroblasts , 2002, Hypertension.

[44]  M. O’Connor-McCourt,et al.  Characterization of recombinant soluble human transforming growth factor-β receptor Type II (rhTGF-βsRII) , 1995 .

[45]  Gregory M. Fomovsky,et al.  Evolution of scar structure, mechanics, and ventricular function after myocardial infarction in the rat. , 2010, American journal of physiology. Heart and circulatory physiology.

[46]  J. Stockand,et al.  Aldosterone stimulates proliferation of cardiac fibroblasts by activating Ki-RasA and MAPK1/2 signaling. , 2003, American journal of physiology. Heart and circulatory physiology.